ArticleJournal of research in health sciences2025
Economic Burden of Tuberculosis in Iran: A Nationwide Analysis by Drug Resistance and Cost Components.
Article in Journal of research in health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a significant global health crisis, regaining its status as the leading cause of death in 2023. Quantifying its economic burden is essential for crafting effective public health strategies. This study aimed to estimate the economic burden of TB in Iran.
methodsA prevalence-based approach was used to estimate the economic burden of TB in Iran, accounting for cost variations across TB types and cost categories. Costs were categorized as direct medical, direct non-medical, and indirect, and were calculated for suspected TB patients as well as for those with drug-sensitive TB, multidrug-resistant TB, and extensively drug-resistant TB. Data were extracted from various sources, including the National Tuberculosis Registration System, national TB diagnosis and treatment guidelines in Iran, official medical service tariffs, and previous studies.
resultsOf 210,544 individuals screened, 7,221 were diagnosed with TB, of whom 81.0% had pulmonary TB and 19.0% had extrapulmonary TB. Drug-sensitive TB accounted for 99.4% of cases, multidrug-resistant TB 0.6%, and extensively drug-resistant TB 0.0%. Diagnostic costs represented 48.0% of the total economic burden (approximately Int'l$4.71 million), while post-diagnosis costs totaled Int'l$5.15 million. Overall, economic burden, including all diagnostic and treatment expenses, amounted to approximately Int'l$9.86 million.
conclusionThis study underscores the significant economic burden of TB in Iran, encompassing both pre-diagnosis and post-diagnosis expenses, with direct medical costs representing the largest component. Effective healthcare strategies and comprehensive public health approaches are crucial to reducing these costs and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.